People · Operator

Walter W. Ogilvie III

Named in public records as an officer, director or promoter · active 2011–2011 · Other Technology

1
Companies
2
Filings
$14.8M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Agilum Healthcare Intelligence, Inc.Other TechnologySeries A$14.8M$13.8M2011
Operator network

Walter W. Ogilvie III at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Cameron Newton · 8 companies · 1 sharedCameron NewtonCameron L. Newton · 1 companies · 1 sharedCameron L. NewtonCary L. McNamara · 1 companies · 1 sharedCary L. McNamaraCARY MCNAMARA · 1 companies · 1 sharedCARY MCNAMARAJOHN KOPCKE · 1 companies · 1 sharedJOHN KOPCKEJohn L. Kopcke · 1 companies · 1 sharedJohn L. KopckeKevin L. McNamara · 1 companies · 1 sharedKevin L. McNamaraMARK MCCURRY · 1 companies · 1 sharedMARK MCCURRYMatthew W. Wiltshire · 1 companies · 1 sharedMatthew W. Wiltsh…PRASAD YAMMANUR · 1 companies · 1 sharedPRASAD YAMMANURRichard A. Bendis · 1 companies · 1 sharedRichard A. BendisRonald Marston · 1 companies · 1 sharedRonald MarstonRoy Mathews · 1 companies · 1 sharedRoy MathewsAgilum Healthcare Intelligence, Inc. · $14.8M raisedAgilum Healthcare Int…Walter W. Ogilvie IIIWI
Walter W. Ogilvie III Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Walter W. Ogilvie III on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Cameron Newton18
Ronald Marston11
Kevin L. McNamara11
Roy Mathews11
John L. Kopcke11
Cary L. McNamara11
Matthew W. Wiltshire11
Richard A. Bendis11
CARY MCNAMARA11
JOHN KOPCKE11
PRASAD YAMMANUR11
Cameron L. Newton11
MARK MCCURRY11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.